Estrella Immunopharma, Inc

ESLANASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

43.5M

on 2026-08-11, from 36.5M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

Filed

S-3 of 2024-12-12. Size not read. 1 prospectus supplement filed under it since. S-3 ↗

$50.0M

White Lion Capital, agreement of 2024-12-05. No at-the-market sales statement read from a 10-Q or 10-K. 8-K ↗

Warrants

2.21M

Warrants of every class as tagged in the XBRL facts on 2024-03-31. 10-Q ↗

Cash

under 0.1 quarters

$100K on 2026-06-30 ÷ $2.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2026-01-06	Public offering	not read	$1.58	$8.0M	424B5 ↗
2026-01-05	Registered direct offering incl. 1.00M pre-funded	2,000,000	not read	$8.0M	8-K ↗
2025-05-30	Private placement	2,233,334	$1.50	$3.4M	8-K ↗